A seemingly simple supplement registry could quietly reshape the entire natural health market—and limit what consumers can access. Action Alert!
Listen to the audio version of this article:
THE TOPLINE
- The proposed Dietary Supplement Listing Act is framed as a transparency measure, but it would effectively create a premarket approval system.
- The compliance burden would likely hit small and innovative supplement companies hardest, leading to market consolidation and fewer niche or practitioner-grade products for consumers.
- A centralized FDA registry could become a tool to target and remove certain supplements, while doing little to stop illegal or adulterated products that already evade existing laws.
Imagine walking into your local health store—or opening your usual online shop—and finding that a supplement you’ve relied on for years is suddenly gone. No warning, no clear explanation. It’s just gone.
For millions of Americans who use vitamins, minerals, and other supplements as part of their daily health routines, this could be the reality if Congress enacts the latest version of Dietary Supplement Listing Act, the bill long championed by Senator Dick Durbin (D-IL), but this time introduced by Representative Maxine Dexter, MD (D-OR).
On its face, the Dietary Supplement Listing Act sounds like a simple transparency measure. Who could oppose a basic product registry? But the reality is, as we’ve argued for years, this bill is the first step towards eliminating supplements you care about.
The Dietary Supplement Health and Education Act—the law governing how supplements are regulated in the US—was designed to treat supplements as a category of food, not drugs, with regulators stepping in when problems arise. This bill flips that logic, creating a de facto premarket approval system akin to how drugs are treated.
The burden won’t fall evenly. Large multinational firms will absorb the compliance costs; smaller companies—the ones driving innovation and offering specialized products—may not. The likely result is market consolidation and reduced consumer choice, particularly for practitioner-grade and niche formulations that don’t fit a mass-market model.
Supporters argue this will improve safety. But FDA already has robust authority to act against adulterated or misbranded supplements. The most serious risks in this space typically stem from illegal products that ignore existing law—not from a lack of paperwork. A sweeping new registry does little to address those bad actors, while imposing new hurdles on responsible companies trying to comply.
More concerning is what comes next. Once a centralized database is in place, the FDA can use the registry as a hit-list to go after supplements it doesn’t like. Maybe high-dose supplements are the first target. Maybe the FDA uses the list to go after supplements that haven’t complied with its over-expansive “new dietary ingredient” guidance (a policy that has yet to be finalized).
At stake here is whether consumers retain broad access to supplements and the freedom to make informed choices about their health. This bill may be framed as modest reform, but its real impact would be anything but modest.
Action Alert!
